NR2B positive allosteric modulators (Luc Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameNR2B positive allosteric modulators (Luc Therapeutics)
Drug Alias NameNR2B modulators (Mnemosyne)NR2B positive allosteric modulators (Mnemosyne)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 modulators
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsSchizophreniaAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCadent Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCadent Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSchizophreniaAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A